Skip to content
Buy This GLP
← Research
Evidence

Semaglutide and C-Reactive Protein: What the Weight and CRP Results Mean

A pooled analysis found that injectable semaglutide reduced weight, waist circumference and CRP more than placebo. Each outcome measures something different.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
Difference in change versus placebobody weight−12.04percentage pointsC-reactive protein−40.9percentage pointsBody weight and CRP are different outcomes.

C-reactive protein, or CRP, is a blood marker of inflammation. Research on GLP-1 drugs and inflammation uses markers like CRP to track changes during treatment. The same percentage change in body weight and CRP would describe different outcomes.

What the review found

The review included nine trials with 6,239 adults who had overweight or obesity without diabetes [1]. Compared with placebo, semaglutide lowered body weight by 12.04 percentage points more from baseline. The 95% confidence interval for that reduction was 11.00 to 13.08 points. Waist circumference fell 9.36 cm more than with placebo.

The pooled difference in CRP change was 40.90 percentage points in favor of semaglutide [1]. The 95% confidence interval was 35.42 to 46.37 points. The studies used different doses and follow-up periods. The review could not separate the effects of weight loss from other possible causes of the CRP changes.

What it found about serious adverse events

The pooled risk ratio for serious adverse events was 1.12, with a 95% confidence interval of 0.76 to 1.65 [1]. Studies of specific digestive side effects address a different question from counting all serious events. The interval leaves room for a lower or higher rate with semaglutide.

Frequently asked

Did semaglutide lower CRP?
The review reported a 40.90-percentage-point greater reduction from baseline than placebo. That result measures a blood marker.
Does the CRP result prove a direct anti-inflammatory effect?
The review could not separate weight-loss effects from other possible causes of the CRP change.
Did serious adverse events differ?
The pooled risk ratio was 1.12, with a 95% confidence interval from 0.76 to 1.65. The estimate remains uncertain.

Sources

  1. [1] Milluzzo A, et al. (2026). Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis International Journal of Obesity. PMID 42668312

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence